Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
RaySearch Laboratories AB ( ($SE:RAY.B) ) has shared an announcement.
RaySearch Laboratories AB reported record high net sales and strong long-term performance in Q3 2025, with a 13% increase in net sales and a 44% rise in operating profit. The company also announced significant collaborations and product launches, including a partnership with Radiology Oncology Systems to expand cancer care access and the introduction of RayIntelligence v2025, an updated analytics platform. These developments are expected to strengthen RaySearch’s market position and enhance its service offerings in oncology.
The most recent analyst rating on ($SE:RAY.B) stock is a Hold with a SEK241.00 price target. To see the full list of analyst forecasts on RaySearch Laboratories AB stock, see the SE:RAY.B Stock Forecast page.
More about RaySearch Laboratories AB
RaySearch Laboratories AB operates in the medical technology industry, focusing on developing advanced software solutions for radiation therapy in cancer treatment. Their primary products include RayStation, a treatment planning system, and RayCare, an oncology information system, which are used globally to enhance cancer care.
Average Trading Volume: 128,831
Technical Sentiment Signal: Buy
Current Market Cap: SEK7.34B
See more insights into RAY.B stock on TipRanks’ Stock Analysis page.